Earnings History Data for Relmada Therapeutics, Inc. (RLMD) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Relmada Therapeutics, Inc.
Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07-11-2024 | AH | RLMD | Relmada Therapeutics, Inc. | 100.18 | -0.72 | -0.65 | -0.73 | Relmada Therapeutics GAAP EPS of -$0.72 misses by $0.08 [11/7/2024 4:32 PM] |
3.24 | -0.02 (-0.61%) |
3.40 | 0.0 (0.00%) |
1.88 - 7.22 | 137,785 | 110,000 | 398 | ||
| 07-08-2024 | AH | RLMD | Relmada Therapeutics | 109.00 | -0.59 | -0.83 | 0.00 | Relmada Therapeutics GAAP EPS of -$0.59 beats by $0.24 [8/7/2024 4:19 PM] |
2.32 | -0.92 (-28.40%) |
0.0 | 0.0 (0.00%) |
2.25 - 7.22 | 678,937 | 60,000 | 0 | ||
| 08-05-2024 | AH | RLMD | Relmada Therapeutics, Inc. | 116.17 | -0.72 | -0.90 | -0.87 | Relmada Therapeutics GAAP EPS of -$0.72 beats by $0.15 [5/9/2024 12:41 PM] |
3.81 | -0.02 (-0.39%) |
0.0 | 0.0 (0.00%) |
2.36 - 7.22 | 85,331 | 90,000 | 0 | ||
| 19-03-2024 | AH | RLMD | Relmada Therapeutics, Inc. | 163.14 | -0.84 | -0.88 | -1.26 | Relmada Therapeutics GAAP EPS of -$0.84 [3/19/2024 4:22 PM] |
4.44 | -0.93 (-17.32%) |
5.37 | 0.0 (0.00%) |
2.00 - 7.22 | 662,198 | 160,000 | 769 | ||
| 08-11-2023 | AH | RLMD | Relmada Therapeutics, Inc. | 94.21 | -0.73 | -0.95 | -1.31 | Relmada Therapeutics GAAP EPS of -$0.73 [11/8/2023 4:17 PM] |
2.96 | -0.04 (-1.33%) |
3.08 | 0.08 (2.67%) |
1.81 - 6.74 | 128,874 | 120,000 | 795 | ||
| 08-08-2023 | AH | RLMD | Relmada Therapeutics, Inc. | 76.45 | -0.84 | -0.92 | -1.33 | Relmada Therapeutics GAAP EPS of -$0.84 beats by $0.06 [8/8/2023 4:44 PM] |
2.73 | 0.19 (7.68%) |
2.62 | 0.08 (3.15%) |
1.81 - 38.68 | 99,785 | 70,000 | 5,701 | ||
| 11-05-2023 | AH | 4:05 PM ET (May 11) |
RLMD | Relmada Therapeutics, Inc. | 101.13 | -0.87 | -1.24 | -1.40 | Relmada Therapeutics GAAP EPS of -$0.87 beats by $0.02 [5/11/2023 4:17 PM] |
2.98 | -0.19 (-5.99%) |
3.17 | 0.0 (0.00%) |
1.81 - 38.68 | 85,884 | 180,000 | 2,807 | |
| 23-03-2023 | AH | 4:05 PM ET (Mar 23) |
RLMD | Relmada Therapeutics, Inc. | 103.09 | -1.26 | -1.38 | -1.80 | Relmada Therapeutics Non-GAAP EPS of -$5.30 misses by $1.28 [3/23/2023 4:02 PM] |
2.25 | -0.07 (-3.02%) |
2.32 | 0.0 (0.00%) |
1.81 - 38.68 | 262,288 | 230,000 | 551 | |
| 11-08-2022 | AH | 4:00 PM ET (Aug 11) |
RLMD | Relmada Therapeutics, Inc. | 711.08 | -1.33 | -1.30 | -1.56 | Relmada Therapeutics GAAP EPS of -$1.33 [8/11/2022 4:20 PM] |
29.21 | 1.39 (5.00%) |
27.74 | -0.08 (-0.29%) |
15.73 - 30.95 | 354,350 | 200,000 | 3,364 | |
| 05-05-2022 | AH | 4:05 PM ET (May 5) |
RLMD | Relmada Therapeutics, Inc. | 761.42 | -1.40 | -1.21 | -1.34 | Relmada Therapeutics GAAP EPS of -$1.40 misses by $0.13 [5/5/2022 5:15 PM] |
21.23 | -1.17 (-5.22%) |
22.37 | -0.03 (-0.13%) |
16.23 - 39.66 | 417,050 | 230,000 | 343 | |
| 23-03-2022 | AH | 4:00 PM ET (Mar 23) |
RLMD | Relmada Therapeutics, Inc. | 632.43 | -1.80 | -1.60 | -1.28 | Relmada Therapeutics GAAP EPS of -$1.80 beats by $0.04 [3/23/2022 4:25 PM] |
25.06 | 1.73 (7.42%) |
23.70 | 0.37 (1.59%) |
16.23 - 40.00 | 437,180 | 279,260 | 646 | |
| 11-11-2021 | AH | 4:05 PM ET (Nov 11) |
RLMD | Relmada Therapeutics, Inc. | 441.19 | -2.44 | -1.62 | -1.05 | Relmada Therapeutics EPS misses by $0.84 [11/11/2021 4:46 PM] |
22.80 | -2.86 (-11.15%) |
25.66 | 0.0 (0.00%) |
20.60 - 40.00 | 128,532 | 60,000 | 1,099 | |
| 10-08-2021 | AH | 4:10 PM ET (Aug 10) |
RLMD | Relmada Therapeutics, Inc. | 394.00 | -1.56 | -1.47 | 0.00 | 23.74 | 0.74 (3.22%) |
21.58 | -1.42 (-6.17%) |
20.60 - 40.87 | 266,205 | 440,000 | 2,045 | ||
| 12-05-2021 | AH | 4:25 PM ET (May 12) |
RLMD | Relmada Therapeutics, Inc. | 578.95 | -1.34 | -1.38 | -0.72 | Relmada Therapeutics EPS beats by $0.06 [5/12/2021 4:27 PM] |
33.30 | -0.31 (-0.92%) |
33.61 | 0.0 (0.00%) |
28.40 - 54.00 | 34,834 | 50,000 | 625 | |
| 23-03-2021 | AH | After the close (Mar 23) |
RLMD | Relmada Therapeutics, Inc. | 593.95 | -1.28 | -1.11 | 0.00 | Relmada Therapeutics EPS misses by $0.25 [3/23/2021 4:31 PM] |
31.93 | -2.41 (-7.02%) |
35.55 | 0.0 (0.00%) |
28.40 - 54.00 | 60,412 | 60,000 | 3,208 | |